<DOC>
	<DOCNO>NCT02752815</DOCNO>
	<brief_summary>This clinical trial compare efficacy safety four cycle R-CHOP follow four cycle Rituximab six cycle R-CHOP follow two cycle Rituximab treatment de novo , low-risk , non-bulky diffuse large B-cell lymphoma .</brief_summary>
	<brief_title>Reduced Chemotherapy Low Risk DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histologically confirm de novo diffuse large Bcell lymphoma , complete response 4 cycle standard RCHOP21 Age &gt; =14 y.o. , &lt; =75 y.o . IPI=01 nonbulky ( large diameter &lt; 7.5cm ) ECOG =01 Life expectancy &gt; 6 month Informed consented Chemotherapy Stem cell transplantation History malignancy , except basal cell squamous cell carcinoma skin carcinoma situ cervix Uncontrollable cardiocerebral vascular , coagulative , autoimmune , serious infectious disease Primary cutaneous , CNS DLBCL LVEFâ‰¤50 % Other uncontrollable medical condition may may interfere participation study Lab enrollment ( unless cause lymphoma ) Neutrophile &lt; 1.5*10^9/L Platelet &lt; 80*10^9/L Hemoglobulin &lt; 100g/L ALT AST &gt; 2*ULN , AKP bilirubin &gt; 1.5*ULN Creatinine &gt; 1.5*ULN Not able comply protocol mental unknown reason Pregnant lactation If HbsAg positive , check HBV DNA , DNA positive patient enrol . If HBsAg negative HBcAb positive ( whatever HBsAb status ) , check HBV DNA , DNA positive patient enrol . HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>